These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 10619261)
1. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261 [TBL] [Abstract][Full Text] [Related]
2. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. O'Connell FP; Pinkus JL; Pinkus GS Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940 [TBL] [Abstract][Full Text] [Related]
3. p27(Kip1) immunostaining for the differential diagnosis of small b-cell neoplasms in trephine bone marrow biopsies. Kremer M; Dirnhofer S; Nickl A; Hoefler H; Quintanilla-Martínez L; Fend F Mod Pathol; 2001 Oct; 14(10):1022-9. PubMed ID: 11598173 [TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177 [TBL] [Abstract][Full Text] [Related]
5. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Martín P; Santón A; Bellas C Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904 [TBL] [Abstract][Full Text] [Related]
6. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Kara IO; Sahin B; Paydas S; Cetiner S Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184 [TBL] [Abstract][Full Text] [Related]
7. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640 [TBL] [Abstract][Full Text] [Related]
8. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases. Coupland SE; Foss HD; Hidayat AA; Cockerham GC; Hummel M; Stein H J Pathol; 2002 Jul; 197(3):333-40. PubMed ID: 12115879 [TBL] [Abstract][Full Text] [Related]
9. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Khalidi HS; Brynes RK; Browne P; Koo CH; Battifora H; Medeiros LJ Mod Pathol; 1998 Oct; 11(10):983-8. PubMed ID: 9796727 [TBL] [Abstract][Full Text] [Related]
10. B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. Tumwine LK; Campidelli C; Righi S; Neda S; Byarugaba W; Pileri SA Hum Pathol; 2008 Jun; 39(6):817-23. PubMed ID: 18436278 [TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 in B lymphoid malignancies. Sanderson RD; Børset M Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737 [TBL] [Abstract][Full Text] [Related]
12. Plasmablastic lymphoma: a clinicopathologic correlation. Folk GS; Abbondanzo SL; Childers EL; Foss RD Ann Diagn Pathol; 2006 Feb; 10(1):8-12. PubMed ID: 16414538 [TBL] [Abstract][Full Text] [Related]
13. Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas. Mazur G; Hałoń A; Wróbel T; Jeleń M; Kuliczkowski K Neoplasma; 2004; 51(3):159-63. PubMed ID: 15254666 [TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535 [TBL] [Abstract][Full Text] [Related]
15. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416 [TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Lin P; Owens R; Tricot G; Wilson CS Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299 [TBL] [Abstract][Full Text] [Related]
17. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma]. Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177 [TBL] [Abstract][Full Text] [Related]
18. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Ng AP; Wei A; Bhurani D; Chapple P; Feleppa F; Juneja S Haematologica; 2006 Jul; 91(7):972-5. PubMed ID: 16818287 [TBL] [Abstract][Full Text] [Related]
19. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Harrington AM; Hari P; Kroft SH Am J Clin Pathol; 2009 Jul; 132(1):60-6. PubMed ID: 19864234 [TBL] [Abstract][Full Text] [Related]
20. Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas. A sensitive and specific marker applicable to formalin-and B5-fixed, paraffin-embedded tissues. Cartun RW; Coles FB; Pastuszak WT Am J Pathol; 1987 Dec; 129(3):415-21. PubMed ID: 3322020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]